Kalita, P and Padhi, AK and Zhang, KYJ and Tripathi, T (2020) Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. In: Microbial Pathogenesis, 145 .
|
PDF
mic_pat_145_2020.pdf - Published Version Download (1MB) | Preview |
|
|
PDF
erratum_mic_pat_160_2021.pdf - Erratum / Correction(s) Download (257kB) | Preview |
Abstract
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority.
| Item Type: | Journal Article |
|---|---|
| Publication: | Microbial Pathogenesis |
| Publisher: | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD |
| Additional Information: | The copyright of this article belongs to Academic Press. |
| Keywords: | peptide vaccine; severe acute respiratory syndrome 2 vaccine; severe acute respiratory syndrome vaccine; unclassified drug, Article; B lymphocyte; coronavirus disease 2019; cytotoxic T lymphocyte; disease control; drug design; drug efficacy; drug potency; drug screening; helper cell; human; immune response; molecular dynamics; nonhuman; pathogenicity; priority journal; Severe acute respiratory syndrome coronavirus 2; validation process; virus entry |
| Department/Centre: | Division of Biological Sciences > Molecular Biophysics Unit |
| Date Deposited: | 11 Aug 2020 09:48 |
| Last Modified: | 13 Jun 2023 05:59 |
| URI: | https://eprints.iisc.ac.in/id/eprint/65418 |
Actions (login required)
 |
View Item |
